Endonovo Therapeutics, Inc. (ENDV): Cash & Equivalents
Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$85.9K
As of 2021-12-31
-39.0%
3-year compound annual growth
+9.1%
5-year compound annual growth
+24.7%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2021-12-31 | $85.9K | +540.4% | 2022-04-14, Balance as of period end |
| 2020-12-31 | $13.4K | -29.0% | 2022-04-14, Balance as of period end |
| 2019-12-31 | $18.9K | -95.0% | 2021-04-13, Balance as of period end |
| 2018-12-31 | $379.2K | +320.5% | 2020-05-04, Balance as of period end |
| 2017-12-31 | $90.2K | +62.4% | 2019-04-15, Balance as of period end |
| 2016-12-31 | $55.5K | +33.9% | 2018-04-06, Balance as of period end |
| 2015-12-31 | $41.5K | n/m | 2017-04-17, Balance as of period end |
| 2014-12-31 | $988 | -69.6% | 2016-05-17, Balance as of period end |
| 2013-12-31 | $3.3K | +306.9% | 2015-06-15, Balance as of period end |
| 2012-12-31 | $800 | -91.5% | 2013-05-03, Balance as of period end |
| 2011-12-31 | $9.4K | -72.8% | 2013-05-03, Balance as of period end |
| 2010-12-31 | $34.8K | n/a | 2012-04-13, Balance as of period end |